Contract
Cancer specialist Hybrigenics SA of Paris has signed a contract to contribute to the large-scale Framework Programme 7 project Masterswitch.
The company will use its protein interaction expertise in the field of chronic inflammatory diseases to develop a high throughput assay, and will screen its 100,000 compound library and collection of 2,000 natural substances to identify small-molecule inhibitors. A hit-to-lead optimisation programme will then be conducted in close collaboration with Frédérique Ponchel at Leeds Institute of Molecular Medicine and Richard Aspinall at the Translational Medicine centre at Cranfield University, both in the UK.
Hybrigenics will receive more than €400,000 over the first two years of the five year-long consortium agreement.
“This EU contract is the recognition at international level of the excellence of Hybrigenics’ expertise in this area of protein interaction assay development and screening," said Rémi Delansorne, CEO at Hybrigenics.
Alongside developing a pipeline of cancer treatments, Hybrigenics offers a range of services to identify, validate and inhibit protein interactions using a high-throughput Yeast-Two Hybrid screening platform.
Masterswitch (Mechanisms to Attack Steering Effectors of Rheumatoid Syndromes With Innovative Therapy Choices) involves a 16-strong consortium coordinated by Tom Huizinga at Leiden University Medical Center. Its main objective is to tackle chronic inflammatory diseases using new therapeutic approaches.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
